Targeting the Synthetic Vulnerability of PTEN-Deficient Glioblastoma Cells with MCL1 Inhibitors
Sign Up to like & getrecommendations! Published in 2020 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.mct-20-0099
Abstract: PTEN deletion or mutation occurs in 30% to 60% of patients with glioblastoma (GBM) and is associated with poor prognosis. Efficacious therapy for this subgroup of patients is currently lacking. To identify potential target(s) to… read more here.
Keywords: gbm cells; synthetic vulnerability; pten deficient; targeting synthetic ... See more keywords
Targeting synthetic lethality: an effective therapeutic approach in ovarian and endometrial cancers
Sign Up to like & getrecommendations! Published in 2025 at "Therapeutic Advances in Medical Oncology"
DOI: 10.1177/17588359251392106
Abstract: Synthetic lethality (SL) is a promising therapeutic concept that relies on the indirect targeting of vulnerabilities acquired through genetic mutations. Ovarian and endometrial cancers frequently exhibit mutations in the breast cancer (BRCA), phosphatase and tensin… read more here.
Keywords: lethality; ovarian endometrial; synthetic lethality; endometrial cancers ... See more keywords